Eli Lilly has announced promising results from its first late-stage trial of a daily pill designed for weight loss and blood sugar management in diabetes patients. The drug, part of the GLP-1 class, could offer an alternative to injectable treatments like Ozempic. Eli Lilly plans to seek FDA approval based on the study’s success. This development could lead to a new wave of obesity treatments in pill form, potentially revolutionizing the market.
— new from The New York Times